Literature DB >> 30926675

The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma.

Umang Swami1, Petros Grivas2,3, Neeraj Agarwal4.   

Abstract

This commentary reviews current progress in neoadjuvant immunotherapy for muscle‐invasive localized urothelial carcinoma, highlighting opportunities and challenges with recent neoadjuvant immunotherapy trials.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30926675      PMCID： PMC6516125          DOI： 10.1634/theoncologist.2019-0161

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  10 in total

1.  A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer.

Authors:  S A Hussain; D H Palmer; B Lloyd; S I Collins; D Barton; J Ansari; N D James
Journal:  Oncol Lett       Date:  2012-01-12       Impact factor: 2.967

2.  Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.

Authors:  Vadim S Koshkin; Pedro C Barata; Lisa A Rybicki; Haris Zahoor; Nima Almassi; Alicia M Redden; Amr F Fergany; Jihad Kaouk; Georges-Pascal Haber; Andrew J Stephenson; Moshe C Ornstein; Timothy Gilligan; Jorge A Garcia; Brian I Rini; Petros Grivas
Journal:  Clin Genitourin Cancer       Date:  2018-02-22       Impact factor: 2.872

3.  Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

Authors:  Atreya Dash; Matthew D Galsky; Andrew J Vickers; Angel M Serio; Theresa M Koppie; Guido Dalbagni; Bernard H Bochner
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

4.  Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-21       Impact factor: 20.096

Review 5.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Authors:  Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora N Sternberg; Dean F Bajorin; Joaquim Bellmunt
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

6.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

Authors:  Gareth Griffiths; Reginald Hall; Richard Sylvester; Derek Raghavan; Mahesh K B Parmar
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

7.  A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.

Authors:  Atreya Dash; Joseph A Pettus; Harry W Herr; Bernard H Bochner; Guido Dalbagni; S Machele Donat; Paul Russo; Mary G Boyle; Matthew I Milowsky; Dean F Bajorin
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

8.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

9.  Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.

Authors:  Zachary D Reardon; Sanjay G Patel; Harras B Zaid; C J Stimson; Matthew J Resnick; Kirk A Keegan; Daniel A Barocas; Sam S Chang; Michael S Cookson
Journal:  Eur Urol       Date:  2014-01-23       Impact factor: 20.096

10.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.